Literature DB >> 11905709

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

A J Dannenberg1, N K Altorki, J O Boyle, C Dang, L R Howe, B B Weksler, K Subbaramaiah.   

Abstract

Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention--the use of drugs or natural substances to inhibit carcinogenesis - is an important and rapidly evolving aspect of cancer research. We discuss evidence that cyclooxygenase 2 (COX 2), an inducible form of the enzyme, is a potential pharmacological target to prevent cancer. Key data implicating a causal relation between increased activity of COX 2 and carcinogenesis and possible mechanisms of action of COX 2 in this context are covered. Importantly, selective COX 2 inhibitors appear to be safe enough in human beings to allow large-scale clinical testing in healthy people. Several chemoprevention trials using selective COX 2 inhibitors are underway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11905709     DOI: 10.1016/S1470-2045(01)00488-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  114 in total

1.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms.

Authors:  Daniel H Hwang; Victor Fung; Andrew J Dannenberg
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

Review 2.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

3.  Cyclooxygenase-2: a potential target in human cancer.

Authors:  Jong-Ho Won
Journal:  Cancer Res Treat       Date:  2004-06-30       Impact factor: 4.679

4.  Effects of the inhibition of cytosolic phospholipase A(2)α in non-small cell lung cancer cells.

Authors:  Shenbagamoorthy Sundarraj; Soundarapandian Kannan; Ramar Thangam; Palani Gunasekaran
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-25       Impact factor: 4.553

Review 5.  [Interaction of anesthetics and analgesics with tumor cells].

Authors:  A Bundscherer; M Malsy; D Bitzinger; B M Graf
Journal:  Anaesthesist       Date:  2014-04       Impact factor: 1.041

6.  Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer.

Authors:  Xiao-Lin Guo; Li-Er Wang; Shu-Yan Du; Chen-Ling Fan; Li Li; Peng Wang; Yuan Yuan
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 7.  Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation.

Authors:  Manuel U Ramirez; Elizabeth R Stirling; Nancy J Emenaker; David D Roberts; David R Soto-Pantoja
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

8.  Resveratrol directly targets COX-2 to inhibit carcinogenesis.

Authors:  Tatyana A Zykova; Feng Zhu; Xiuhong Zhai; Wei-Ya Ma; Svetlana P Ermakova; Ki Won Lee; Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2008-10       Impact factor: 4.784

9.  Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.

Authors:  Karin Muller-Decker; Gitta Neufang; Irina Berger; Melanie Neumann; Friedrich Marks; Gerhard Furstenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-09       Impact factor: 11.205

10.  The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells.

Authors:  Cornelia Czembirek; Christina Eder-Czembirek; Boban M Erovic; Dritan Turhani; Andreas Spittler; Edgar Selzer; Richard Pötter; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.